Holen Sie sich die Stockscreener-App
1.74
4.82%
0.08
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Brokers Issue Forecasts for ZNTL FY2029 Earnings - Defense World
FY2029 Earnings Forecast for ZNTL Issued By HC Wainwright - MarketBeat
Equities Analysts Offer Predictions for ZNTL FY2029 Earnings - MarketBeat
Zentalis stock price target cut to $10 by H.C. Wainwright - MSN
Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis stock plunges to 52-week low of $1.76 amid market challenges - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $6.00 Price Target at Wells Fargo & Company - MarketBeat
Jefferies cuts Zentalis stock target to $2.50; maintains hold - MSN
Vanguard Group Inc. Reduces Stake in Zentalis Pharmaceuticals Inc. - GuruFocus.com
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 17.5% - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis price target lowered to $6 from $8 at Wells Fargo - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $10.00 Price Target at HC Wainwright - MarketBeat
Zentalis Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ZNTL) - MarketBeat
Zentalis price target lowered to $10 from $20 at Oppenheimer - Yahoo Finance
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis to cut 40% of workforce, focus on azenosertib - MSN
UBS Group Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZNTL) - Defense World
Oppenheimer cuts Zentalis stock target to $10, maintains rating By Investing.com - Investing.com UK
Zentalis Pharmaceuticals Announces New Study for Azenosertib - TipRanks
Zentalis reports progress in ovarian cancer study - MSN
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Shares Updated Clinical Data - GlobeNewswire
Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 35% Success Rate - StockTitan
Zentalis Pharmaceuticals to Cut 40% of Workforce -January 29, 2025 at 03:41 am EST - Marketscreener.com
Zentalis Pharmaceuticals Restructures to Advance Oncology Product - TipRanks
Zentalis to Cut 40% of Workforce to Back Development of Cancer-Drug Azenosertib - MarketWatch
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development - GlobeNewswire
Major Shakeup at Zentalis: Cancer Drug Developer Slashes Jobs to Double Down on Breakthrough Treatment - StockTitan
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Lowered to $2.20 at UBS Group - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Neutral” Rating from Wedbush - Defense World
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
Zentalis Pharmaceuticals' (ZNTL) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by JPMorgan Chase & Co. - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Barclays PLC - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 17.5% in December - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - MarketBeat
Why Zentalis Pharma Is Worth Watching - RTTNews
Zentalis stock plunges to 52-week low of $2.64 amid market challenges - Investing.com Canada
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Zentalis Pharmaceuticals, Inc. Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - Marketscreener.com
Zentalis Gets FDA Fast-Track Designation for Azenosertib - MarketWatch
Zentalis Pharmaceuticals Announces Azenosertib Fast Track - GlobeNewswire
Zentalis' Cancer Drug Azenosertib Receives FDA Fast Track Status for Ovarian Cancer Treatment - StockTitan
Geode Capital Management LLC Has $4.76 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Barclays PLC Buys 11,748 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Jane Street Group LLC Sells 11,796 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):